Q-omics provides the consensus-scored CDKN2A profile across patient tissues and cancer cell-line models. CDKN2A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CDKN2A is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, CDKN2A RNA expression shows 11,988 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where CDKN2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDKN2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDKN2A survival associations across molecular data types. CDKN2A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDKN2A RNA expression–survival associations across cancer types. High CDKN2A expression shows unfavorable associations in ACC, COAD, UCEC, UVM and LIHC, but favorable associations in MESO. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CDKN2A RNA expression.
This table summarizes CDKN2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CDKN2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDKN2A shows higher tumor expression in HNSC, KIRC, KICH, COAD, KIRP and THCA. The HNSC box plot shows higher CDKN2A RNA expression in tumor versus normal tissue (log2 FC = +3.163, t-test p < 0.001).
This table shows molecular features associated with CDKN2A in patient tissues and cancer cell lines. In patient samples, CDKN2A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CDKN2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
